Systematic Review in Clopidogrel Therapy Coronary Heart Disease with Chronic Nephropathy

ZHANG Li,ZHAI Suo-di
2010-01-01
Abstract:OBJECTIVE To evaluate the safety and effect of clopidogel in coronary artery disease with chronic nephropathy.METHODS Data were reviewed in MEDLINE(1977-2009),EMBASE(1989-2009),Cochrane library 2009(6),CBMdisc(1978-2009) and CNKI(1994-2009).Meta analysis was performed with RevMan 5.0 software supplied by Cochrane Collaboration.RESULTS 29 858 cases were ontained from three Randomized controlled trials(RCTs).The difference between clopidogel-treated and control groups was statistical significance,for stochastic effect model [OR=0.88,95%CI(0.82,0.95),P0.01].Combination analysis of bleeding in the end of follow-up period showed there was statistical significance,OR=1.59,95%CI(1.42,1.77),P0.000 01.Less events happed in treatment group in stage 1 and stage 2 among CKD patients.More bleed cases were obtained in clopidogrel treated group than those in control group during stage 3 CKD[OR=1.12,95%CI(0.99,1.27),P=0.08].Bleed cases in Stage 1,2,3 CKD showed higher incidence rate in clopidogrel treated group than those in placebo group.CONCLUSION Higher incidence rate of cardiovascular death,myocardial infarction,apoplexy and bleeding were found in clopidogrel treated CHD patients during stage 3 CKD.
What problem does this paper attempt to address?